Video

Dr. Parker on next steps with mpMRI in prostate cancer

Author(s):

Urology Times staff

William P. Parker, MD, shares his expectations for the future of multiparametric MRI (mpMRI) in prostate cancer and where micro-ultrasound may fit alongside mpMRI in the paradigm. Parker is a practicing urologist at The University of Kanas Health System and an assistant professor at the University of Kansas Medical Center.

Related Videos
Eric Li, MD, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Jitesh Dhingra, MD, FRCEM, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Jitesh Dhingra, MD, FRCEM, answers a question during a Zoom video interview
Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Related Content
Collaboration to support phase 3 SECuRE trial of 67Cu-SAR-bisPSMA
November 12th 2024

Collaboration to support phase 3 SECuRE trial of 67Cu-SAR-bisPSMA

Hannah Clarke
The phase 1/2a SECuRE trial is evaluating the safety and efficacy of 67Cu-SAR-bisPSMA in the treatment of patients with mCRPC.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023

Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer

Urology Times staff
"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
CMS adjusts reimbursement for diagnostic radiopharmaceuticals
November 5th 2024

CMS adjusts reimbursement for diagnostic radiopharmaceuticals

Hannah Clarke
The revised policy will take effect on January 1, 2025.
Dr. Bristol Whiles discusses her experience as a urology resident
July 25th 2022

Dr. Bristol Whiles discusses her experience as a urology resident

Kansas University Department of Urology
On this podcast, Bristol Whiles, MD, discusses her urology residency experience at the Kansas University School of Medicine Department of Urology.
Trial launches of 61Cu-based radiotracer in PSMA-positive prostate cancer
October 23rd 2024

Trial launches of 61Cu-based radiotracer in PSMA-positive prostate cancer

Hannah Clarke
The trial is comparing the diagnostic performance of 61Cu-NODAGA-PSMA I&T with that of 18F-piflufolastat.
68Ga-PSMA and 18F-Fluciclovine demonstrate ability to alter radiation target volumes
October 16th 2024

68Ga-PSMA and 18F-Fluciclovine demonstrate ability to alter radiation target volumes

Hannah Clarke
Data from the EMPIRE-2 trial also showed that 18F-fluciclovine resulted in significantly more boosts to the prostate bed.
© 2024 MJH Life Sciences

All rights reserved.